BUZZ Archives | Psychedelic Invest

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study

Press

PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease

Aug 5 • 4 min read

Quick Take: PharmaDrug has formed a partnership with a biotechnology institute to research DMT therapy for eye diseases. PharmaDrug Inc. (CSE: PHRX), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that PharmaDrug has entered into…

Press

Pharmadrug’s Supersmart Launches Psilocybin Online Retail Platform in the Netherlands

Jun 7 • 4 min read

Quick Take: PharmaDrug has launched an online retail platform in The Netherlands and Europe. The online store will sell psilocybin truffles and functional mushrooms. PharmaDrug Inc. (CSE: BUZZ) a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to…

Press

PharmaDrug Files For FDA Orphan Drug Designation For DMT

Feb 25 • 5 min read

PharmaDrug Inc. announced it has expanded its psychedelic pharmaceutical program with the filing of an application with the U.S. Food and Drug Administration.

Press

PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke

Feb 12 • 4 min read

PharmaDrug Inc. announced it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation for N,N-Dimethyltryptamine (“DMT”).